April 26, 2017 05:12 PM EDT
People
R&D
Pharma

Scan­gos left Bio­gen in style, tak­ing a fi­nal $17.7M com­pen­sa­tion pack­age for one last, dis­ap­point­ing year

John Carroll

Editor & Founder

When George Scan­gos left Bio­gen at the end of 2016, he left be­hind a fad­ing megablock­buster fran­chise he had helped cre­ate and passed the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times